Innovative technologies for automated biomarkers extraction and machine-learning
Our patent-pending methods utilize sensitive MRI/PET/SPECT measures with meaningful clinical data to deliver precise and interpretable scores, presented in comparison to gender and age-appropriate reference charts. Measures are inputs for the classification algorithm as illustrated below:
Quantification of hippocampal atrophy
Changes in MRI/PET/SPECT biomarkers preceed symptom onset in subjects with neurological disorders, as depicted below for dementia:
Qynapse® helps effectively measure these biomarkers that enable more accurate diagnosis and disease management.